Diabetic Kidney Disease

Diabetic Kidney Disease
Departemen Ginjal Hipertensi

SMF Ilmu Penyakit Dalam
FK UNS/ RS Dr Moewardi Surakarta
Oleh:
Fitria kusumawardani
Pembimbing:
Dr. Wachid putranto, Sp.PD-KGH, FINASIM
Diabetic nephropathy is a clinical

syndrome characterized by the following:
1.Persistent albuminuria (>300 mg/d or
>200 g/min) that is confirmed on at
least 2 occasions 3-6 months apart
2.Progressive decline in the glomerular
filtration rate (GFR)
3.Elevated arterial blood pressure
Three major histologic changes occur in the

glomeruli of persons with diabetic nephropathy.
1.First, mesangial expansion is directly induced by
hyperglycemia, perhaps via increased matrix
production or glycation of matrix proteins.
2.Second, thickening of the glomerular basement
membrane (GBM) occurs.
3.Third, glomerular sclerosis is caused by
intraglomerular hypertension (induced by
dilatation of the afferent renal artery or from
ischemic injury induced by hyaline narrowing of
the vessels supplying the glomeruli).
Pathophysiology
Etiology
The
exact cause of diabetic nephropathy is

unknown, but various postulated
mechanisms are hyperglycemia (causing
hyperfiltration and renal injury)
Evidence suggests that when there is
insulin resistance, the pancreas is forced
to increase its insulin output, which
stresses the cells, eventually resulting in
-cell exhaustion.
The high blood glucose levels and high levels

of saturated fatty acids create an
inflammatory medium, resulting in activation
of the innate immune system, which results
in activation of the nuclear transcription
factors-kappa B (NF-B), and release of
inflammatory mediators, including,
interleukin (IL)1 and tumor necrosis factor
(TNF), promoting systemic insulin
resistance and -cell damage as a result of
autoimmune insulitis. Hyperglycemia and
high serum levels of free fatty acids and IL-1
lead to glucotoxicity, lipotoxicity, and IL-1
toxicity, resulting in apoptotic -cell death.
Hyperglycemia
also increases the

expression of transforming growth factor-
(TGF-) in the glomeruli and of matrix
proteins, specifically stimulated by this
cytokine. TGF- and vascular endothelial
growth factor (VEGF) may contribute to
the cellular hypertrophy and enhanced
collagen synthesis and may induce the
vascular changes observed in persons with
diabetic nephropathy
Prevalence
of
diabetic
The severity and incidence of diabetic
nephropathy
race great in blacks
nephropathy areby
especially
(the frequency being 3- to 6-fold higher than

it is in whites)
The relatively high frequency of the condition
in these genetically disparate populations
suggests that socioeconomic factors, such as
diet, poor control of hyperglycemia,
hypertension, and obesity, have a primary
role in the development of diabetic
nephropathy. It also indicates that familial
clustering may be occurring in these
populations.
Prognosis
Proteinuria is a predictor of morbidity and

mortality.
Patients in whom proteinuria did not develop
have a low and stable relative mortality rate,
whereas patients with proteinuria have a 40fold higher relative mortality rate.
Cardiovascular disease is also a major cause
of death (15-25%) in persons with
nephropathy and type 1 DM, despite their
relatively young age at death.
Diagnosis
Diagnosis is usually based on the
measurement of high levels of albumin in
the urine or evidence of reduced kidney
function
1.Normal albuminuria: urinary albumin
excretion <30 mg/24h;
2.Microalbuminuria: urinary albumin
excretion in the range of 30299 mg/24h;
3.Clinical (overt) albuminuria: urinary
albumin excretion 300 mg/24h.
DN can be divided into five stages:

1) early hypertrophy stage characterized by
increase in renal plasma flow and GFR
2) silent stage, which is associated with subtle
morphological changes, including thickening of
the glomerular basement membrane,
glomerular hypertrophy, mesangial, and
tubulointerstitial expansion
3) incipient DN characterized by microalbuminuria
with likely onset of hypertension
4) overt DN characterized by dipstick-positive
proteinuria
5) end-stage renal disease (ESRD) with uremia.
(Mogensen et al)
*
*
*
*
*
*
*
*
Genetic susceptibility
Race
Elevated blood pressure
Elevated blood sugar
Hyperfiltration
Age
Male gender
Dyslipidemia
Diabetic Nephropathy Risk Factors
CKD Stage[8]
eGFR level (mL/min/1.73 m2)
Stage 1
90
Stage 2
60 89
Stage 3
30 59
Stage 4
15 29
Stage 5
< 15
Treatment Interventions in
Diabetic Nephropathy
*
Glycemic control
* Treatment of hypertension
* Cessation of smoking
* Protein restriction
* Control of dyslipidemia
* Renal replacement therapy
* Multifactorial approach
* Combined therapy targeting :
hyperglycaemia, hypertension, and
dyslipidemia.
The American Diabetes Association recommends

that treatment aim at achieving target
pre-prandial glucose of 80-120 mg/dL (whole
blood) or 90-130 mg/dL (plasma)
bedtime glucose of 100-140 mg/dL (whole blood)
or 1 10150 mg/dL (plasma), and HbA1c <7%/
Target blood sugar levels can be achieved using
oral hypoglycemic agents, insulin, or a
combination of both.
Glycemic Control
Goal Blood Pressure

(mm Hg)
Recommended Blood
Pressure Agents
130/80
ACEI; ARB if ACEI not

tolerated; diuretic as
second-line agent
130/80
ARB; ACEI as
alternative; diuretic as
second-line agent
130/80
Angiotensin blockade in
conjunction with
diuretic; beta blocker or
calcium channel blocker
as third-line agent
Diabetic with congestive

130/80
heart failure
ACEI remains a first-line

agent, followed by beta
blocker
Diabetic with coronary

artery disease
Beta blocker is first-line

agent, followed by ACEI;
diuretic as third-line
agent
Patient
Type 1 diabetic
Type 2 diabetic
Diabetic with
macroalbuminuria
130/80
Loss
of renal function is slower in those

who stopped smoking. Cessation of
smoking alone may reduce the risk of
progression by 30% in patients with type2 diabetes.
Cessation of Smoking
stabilize
renal restriction protein intake to

0.8 g/kg body weight per day, which is
consistent with the recommended daily
allowance, has been shown to reduce the
rate of progression to ESRD in patients
with type-I diabetes in another study
The National Kidney Foundation
recommends that patients with GFR <29
mL/min per 1.73m2 should have a daily
protein intake of 0.6 g/kg body weight.
Protein Restriction
meta-analysis of 13 controlled trials involving a

total of 362 subjects, 253 had diabetes, showed
that statins decreased proteinuria and preserved
GFR in patients with chronic renal disease.These
effects could not be entirely explained by a
reduction in blood cholesterol. Adequately
powered randomized controlled trials will be
needed to determine the role of lipid lowering
therapy in retarding the rate of decline in kidney
function in patients with diabetes mellitus.
hyperlipidemia
* Control of blood sugar (ADA Targets)

Preprandial glucose: 80-120 mg/dL (whole blood) 90-130 mg/dL
(plasma)
Bedtime glucose: 100-140 mg/dL (whole blood)
Glycosylated hemoglobin: <7%
* Control of Blood Pressure (ADA, NKF Targets)
110-150 mg /dL (plasma)
<130/80 mm Hg in patients with proteinuria <1 g/day.
<125/75 mm Hg in patients with proteinuria .1 g/day.
* Control of Blood Lipids (ADA Targets)
LDL cholesterol <100 mg/dL (first priority)
HDL cholesterol >45 mg/dL (second priority)
Triglycerides <200 mg/dL (second priority)
(ADA-American Diabetes Association; NKF-National Kidney
Foundation)
Multifactorial Approach in the

Management of Diabetic
Nephropathy
DN remains the leading cause of ESRD in developed

countries, and its prevalence seems to be Increasing
The cost of treating this condition, particularly when patients
require renal replacement therapy, is enormous. In order to
achieve the Healthy People 2010 goal of 78 diabetic persons
with new cases of ESRD per million population,
a multifactorial approach targeting strict control of blood
sugar, lipids, and blood pressure and use of ACEIs and ARBs
in proteinuric patients will be preferable.
In addition, low-cost community-based programs to increase
physical activity and avoid unhealthy lifestyle choices should
be encouraged, since this will lead to reduction in the
incidence of diabetes in the populace.
CONCLUSION
thankyou

Diabetic Kidney Disease

Uploaded by

Copyright:

Available Formats

Diabetic Kidney Disease

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Diabetic Kidney Disease

Uploaded by

Copyright:

Available Formats

Diabetic Kidney Disease

Departemen Ginjal Hipertensi

Diabetic nephropathy is a clinical

Three major histologic changes occur in the

exact cause of diabetic nephropathy is

The high blood glucose levels and high levels

also increases the

(the frequency being 3- to 6-fold higher than

Proteinuria is a predictor of morbidity and

DN can be divided into five stages:

Diabetic Nephropathy Risk Factors

eGFR level (mL/min/1.73 m2)

The American Diabetes Association recommends

Goal Blood Pressure

ACEI; ARB if ACEI not

Diabetic with congestive

ACEI remains a first-line

Diabetic with coronary

Beta blocker is first-line

of renal function is slower in those

renal restriction protein intake to

meta-analysis of 13 controlled trials involving a

* Control of blood sugar (ADA Targets)

Multifactorial Approach in the

DN remains the leading cause of ESRD in developed

You might also like